Efficacy and safety of R2 regimen as short-cycle maintenance therapy for patients with B-cell non-Hodgkin lymphoma

Xiaoguo WANG; Fanyi MENG; Shunhua HUANG; Jianhua YU; Qingxiu ZHONG; Hongyu CHEN; Mingyan WU; Baoyi YUAN; Dana YAO

Return

Efficacy and safety of R2 regimen as short-cycle maintenance therapy for patients with B-cell non-Hodgkin lymphoma

VernacularTitle:B细胞非霍奇金淋巴瘤患者R2方案短周期维持治疗的效果及安全性
Author: Xiaoguo WANG ¹ ; Fanyi MENG ¹ ; Shunhua HUANG ¹ ; Jianhua YU ¹ ; Qingxiu ZHONG ¹ ; Hongyu CHEN ¹ ; Mingyan WU ¹ ; Baoyi YUAN ¹ ; Dana YAO ¹
Author Information

1. 东莞康华医院血液淋巴瘤科，东莞　523000
Publication Type:Journal Article
Keywords: Lymphoma, non-Hodgkin; Lenalidomide; Rituximab; Prognosis; Adverse reactions
From: Cancer Research and Clinic 2025;37(6):435-439
CountryChina
Language:Chinese
Abstract: Objective:To explore the efficacy and safety of the combination therapy of lenalidomide and rituximab (R2) for short-cycle maintenance therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL).Methods:A retrospective case series study was conducted. The clinical data of 19 B-NHL patients who received R2 regimen maintenance therapy after achieving complete remission through chemotherapy or autologous hematopoietic stem cell transplantation at Dongguan Kanghua Hospital from February 2018 to January 2024 were collected, and the overall survival (OS), progression-free survival (PFS), adverse reactions, changes in lymphocyte subsets and cytokine levels before and after treatment were analyzed.Results:Among the 19 patients, there were 7 males and 12 females, with a median age [ M ( Q1, Q3)] of 49 (45, 65) years. The median follow-up time was 56 months, ranging from 5 to 77 months. The 1-year OS and PFS rates were 89.2% and 88.9%, respectively. The 2-year and 5-year PFS rates were both 83.2%, and the 2-year and 5-year OS rates were both 88.9%. Common adverse reactions included hematological adverse reactions and infections, with 4 cases (21.1%) experiencing grade 3-4 hematological adverse reactions and 4 cases (21.1%) experiencing infections. There was no statistically significant difference in the levels of lymphocyte subsets (total T cells, helper T cells, regulatory T cells, NK cells, B cells, and CD4/CD8) and cytokines [interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-α, and interferon-γ] before and after treatment (all P > 0.05). Conclusions:The R2 regimen for short-cycle maintenance therapy of B-NHL is effective and well tolerated by patients.